Shahrzad Arya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shahrzad Arya has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Luke Maggs
Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
22 shared publications - Bruce R. Ksander
Schepens Eye Research Institute of Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, United States
21 shared publications - Cristina R. Ferrone
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
21 shared publications - Genevieve Marie Boland
Massachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, USA
21 shared publications - Giulia Cattaneo
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
21 shared publications - Jingyu Jia
Department of Orthopedics, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang City, China
21 shared publications
Latest Publications
- 19 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 644, 218345
Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer
- 19 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 644, 218345
Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Surgery
Long-term Outcomes of Spleen-preserving Distal Pancreatectomy With or Without Preservation of Splenic Vessels
Objective: To compare the short- and long-term outcomes of the Warshaw (splenic vessel resection) and Kimura (splenic vessel preservation) techniques in spleen-preserving distal pancreatectomy (SPDP). Summary Background Data: SPDP is an alternative to splenectomy that preserves immune function. Both Warshaw and Kimura are used, but comparative data on their long-term safety and indications are limited. Methods: Retrospective bi-institutional analysis of 297 patients undergoing SPDP at Massachusetts General Hospital and Cedars-Sinai Medical Center (2002–2020). Clinicopathologic, operative, and radiologic outcomes were compared. Results: Of 297 patients, 245 (82.5%) underwent Warshaw and 52 (17.5%) Kimura. Warshaw was more commonly performed for larger tumors (2.5 cm vs. 1.5 cm, P P disease , Kimura was more commonly performed minimally invasively (MIS) (73.1% vs. 44.1%, P Higher ASA class, larger tumor size, pancreatic ductal adenocarcinoma, and the Warshaw technique independently predicted longer operative time in MIS cases, suggesting a preferential adoption of the Warshaw technique for technically more challenging tumor dissections. Short-term morbidity , readmission, and mortality rates were comparable. With a median follow-up of 85.8 monthssplenic hypoperfusion (30.4% vs. 12.2%, P =0.010), and perigastric varices (19.6% vs. 7.3%, P =0.056) were more frequent after Warshaw, although most were clinically silent, and the need for secondary splenectomy was rare (1.2%). Conclusions: Both techniques are safe and effective for SPDP. Warshaw is preferred for proximal, malignant, or complex lesions, while Kimura may minimize long-term splenic sequelae in small, distal, benign tumors. An anatomy- and disease -driven approach remains essential to optimize outcomes.
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Surgery
Long-term Outcomes of Spleen-preserving Distal Pancreatectomy With or Without Preservation of Splenic Vessels
Objective: To compare the short- and long-term outcomes of the Warshaw (splenic vessel resection) and Kimura (splenic vessel preservation) techniques in spleen-preserving distal pancreatectomy (SPDP). Summary Background Data: SPDP is an alternative to splenectomy that preserves immune function. Both Warshaw and Kimura are used, but comparative data on their long-term safety and indications are limited. Methods: Retrospective bi-institutional analysis of 297 patients undergoing SPDP at Massachusetts General Hospital and Cedars-Sinai Medical Center (2002–2020). Clinicopathologic, operative, and radiologic outcomes were compared. Results: Of 297 patients, 245 (82.5%) underwent Warshaw and 52 (17.5%) Kimura. Warshaw was more commonly performed for larger tumors (2.5 cm vs. 1.5 cm, P P disease , Kimura was more commonly performed minimally invasively (MIS) (73.1% vs. 44.1%, P Higher ASA class, larger tumor size, pancreatic ductal adenocarcinoma, and the Warshaw technique independently predicted longer operative time in MIS cases, suggesting a preferential adoption of the Warshaw technique for technically more challenging tumor dissections. Short-term morbidity , readmission, and mortality rates were comparable. With a median follow-up of 85.8 monthssplenic hypoperfusion (30.4% vs. 12.2%, P =0.010), and perigastric varices (19.6% vs. 7.3%, P =0.056) were more frequent after Warshaw, although most were clinically silent, and the need for secondary splenectomy was rare (1.2%). Conclusions: Both techniques are safe and effective for SPDP. Warshaw is preferred for proximal, malignant, or complex lesions, while Kimura may minimize long-term splenic sequelae in small, distal, benign tumors. An anatomy- and disease -driven approach remains essential to optimize outcomes.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S3. Correlation between clinicopathological characteristics of patients with primary ocular UM tumors from the Leiden University Medical Center cohort and B7-H3 mRNA expression.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S3. Correlation between clinicopathological characteristics of patients with primary ocular UM tumors from the Leiden University Medical Center cohort and B7-H3 mRNA expression.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S2. Score of B7-H3 expression and clinical information of metastatic UM tissue samples.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S2. Score of B7-H3 expression and clinical information of metastatic UM tissue samples.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Purpose:Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with systemic diseases for which there are no effective treatment strategies. Here we investigated the preclinical efficacy of a chimeric antigen receptor (CAR) T-cell–based immunotherapy targeting B7-H3.Experimental Design:B7-H3 expression on primary and metastatic human UM samples and cell lines was assessed by RNA sequencing, flow cytometry, and immunohistochemistry. Antitumor activity of CAR T cells targeting B7-H3 was tested in vitro with UM cell lines, patient-derived organotypic tumor spheroids from patients with metastatic UM, and in immunodeficient and humanized murine models.Results:B7-H3 is expressed at high levels in >95% UM tumor cells in vitro and in vivo. We generated a B7-H3 CAR with an inducible caspase-9 (iCas9) suicide gene controlled by the chemical inducer of dimerization AP1903, which effectively kills UM cells in vitro and eradicates UM liver metastases in murine models. Delivery of iCas9.B7-H3 CAR T cells in experimental models of UM liver metastases demonstrates a durable antitumor response, even upon tumor rechallenge or in the presence of a significant metastatic disease burden. We demonstrate effective iCas9.B7-H3 CAR T-cell elimination in vitro and in vivo in response to AP1903. Our studies demonstrate more effective tumor suppression with iCas9.B7-H3 CAR T cells as compared to a B7-H3-targeted humanized monoclonal antibody.Conclusions:These studies support a phase I clinical trial with iCas9.B7-H3 CAR T cells to treat patients with metastatic UM.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Purpose:Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with systemic diseases for which there are no effective treatment strategies. Here we investigated the preclinical efficacy of a chimeric antigen receptor (CAR) T-cell–based immunotherapy targeting B7-H3.Experimental Design:B7-H3 expression on primary and metastatic human UM samples and cell lines was assessed by RNA sequencing, flow cytometry, and immunohistochemistry. Antitumor activity of CAR T cells targeting B7-H3 was tested in vitro with UM cell lines, patient-derived organotypic tumor spheroids from patients with metastatic UM, and in immunodeficient and humanized murine models.Results:B7-H3 is expressed at high levels in >95% UM tumor cells in vitro and in vivo. We generated a B7-H3 CAR with an inducible caspase-9 (iCas9) suicide gene controlled by the chemical inducer of dimerization AP1903, which effectively kills UM cells in vitro and eradicates UM liver metastases in murine models. Delivery of iCas9.B7-H3 CAR T cells in experimental models of UM liver metastases demonstrates a durable antitumor response, even upon tumor rechallenge or in the presence of a significant metastatic disease burden. We demonstrate effective iCas9.B7-H3 CAR T-cell elimination in vitro and in vivo in response to AP1903. Our studies demonstrate more effective tumor suppression with iCas9.B7-H3 CAR T cells as compared to a B7-H3-targeted humanized monoclonal antibody.Conclusions:These studies support a phase I clinical trial with iCas9.B7-H3 CAR T cells to treat patients with metastatic UM.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S4. Macroscopic and microscopic inspection of livers from low and high tumor burden mice treated with iCas9.B7-H3 CAR T cells.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S4. Macroscopic and microscopic inspection of livers from low and high tumor burden mice treated with iCas9.B7-H3 CAR T cells.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S2. In vitro assessment of B7-H3 CAR T cell antitumor activity.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S2. In vitro assessment of B7-H3 CAR T cell antitumor activity.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S2. In vitro assessment of B7-H3 CAR T cell antitumor activity.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S2. In vitro assessment of B7-H3 CAR T cell antitumor activity.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S5. Phenotype of circulating immune cells in humanized mice.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Figure S5. Phenotype of circulating immune cells in humanized mice.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S1. Score of B7-H3 expression of treatment-naïve primary UM tumor samples.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Supplementary Table S1. Score of B7-H3 expression of treatment-naïve primary UM tumor samples.